OUP user menu

Journal of Crohn's and Colitis: 10 (9)


Laurence J. Egan, Ireland

Associate Editors

Shomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKJesús Rivera-Nieves, USABritta Siegmund, GermanyGijs van den Brink, NLSéverine Vermeire, Belgium


Published on behalf of

Infliximab for treatment of pyoderma gangrenosum with ulcerative colitis

Beuy Joob, Viroj Wiwanikit
DOI: http://dx.doi.org/10.1016/j.crohns.2012.08.018 e153 First published online: 1 May 2013

Dear Sir,

The recent case report published in the JCC on using combined infliximab and surgery in treatment of pyoderma gangrenosum with ulcerative colitis is interesting.1Andrisani et al. proposed for the effectiveness of this regimen.1The possibility of adverse events on the other side on using infliximab should also be mentioned. The practitioner has to weigh between the usefulness and possible adverse side effect in each individual case.2A recent report on the possible relation between using infliximab and Guillain–Barre and Miller Fisher syndromes in a case with ulcerative colitis should be mentioned.3The close monitoring for development of immune related symptoms in any immunological disorder cases with monoclonal antibodies including infliximab should be done.3

Conflict of interest

Both authors do not have conflicts of interest to declare.


View Abstract